Potential therapeutic treatments of cancer-induced bone pain
| Autor: | Holly Ellingson, Todd W. Vanderah |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Standard of care
medicine.medical_treatment Critical Care and Intensive Care Medicine Bioinformatics Antiporters Bone and Bones Article Mice 03 medical and health sciences 0302 clinical medicine Receptor Cannabinoid CB1 medicine Animals Humans 030212 general & internal medicine Bone pain Receptor Sphingosine-1-Phosphate Receptors Cannabinoids Oncology (nursing) business.industry Receptors Opioid kappa Glutamate receptor Cancer Cancer Pain General Medicine medicine.disease Disease Models Animal 030228 respiratory system Oncology Opioid Cannabinoid medicine.symptom Cancer pain business medicine.drug |
| Zdroj: | Curr Opin Support Palliat Care |
| ISSN: | 1751-4266 1751-4258 |
| Popis: | Purpose of review The treatment of cancer-induced bone pain (CIBP) has been proven ineffective and relies heavily on opioids, the target of highly visible criticism for their negative side effects. Alternative therapeutic agents are needed and the last few years have brought promising results, detailed in this review. Recent findings Cysteine/glutamate antiporter system, xc, cannabinoids, kappa opioids, and a ceramide axis have all been shown to have potential as novel therapeutic targets without the negative effects of opioids. Summary Review of the most recent and promising studies involving CIBP, specifically within murine models. Cancer pain has been reported by 30-50% of all cancer patients and even more in late stages, however the standard of care is not effective to treat CIBP. The complicated and chronic nature of this type of pain response renders over the counter analgesics and opioids largely ineffective as well as difficult to use due to unwanted side effects. Preclinical studies have been standardized and replicated while novel treatments have been explored utilizing various alternative receptor pathways: cysteine/glutamate antiporter system, xc, cannabinoid type 1 receptor, kappa opioids, and a ceramide axis sphingosine-1-phosphate/sphingosine-1-phosphate receptor 1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|